SKYEPHARMA TO PRESENT AT THE JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE

LONDON, UK, 05 June, 2014 - Skyepharma PLC (LSE: SKP), the expert oral and inhalation drug delivery company, today announces that the Company's CEO, Peter Grant, will present at the Jefferies 2014 Global Healthcare Conference in New York on Thursday, 5 June, 2014 at 11:30 a.m. Eastern Time (ET), 4:30 p.m. British Summer Time (BST).  A copy of the presentation is available on the Investor Relations section of the Skyepharma website at

http://www.skyepharma.com/Investors/Presentations_and_webcasts/Default.aspx?id=25

A webcast of the presentation will also be available on the Skyepharma website after the conference.

The Company is also pleased to note that, following a review by the FTSE's Europe, Middle East and Africa Regional Advisory Committee on 4 June, its shares will be included in the FTSE SmallCap and FTSE All-Share indices with effect from the market close on 20 June 2014.

- Ends -

For further information please contact:

Skyepharma PLC

Peter Grant, Chief Executive Officer

Andrew Derodra, Chief Financial Officer

+44 207 881 0524

FTI Consulting

Julia Phillips/Natalie Garland-Collins

+44  203 727 1000

N+1 Singer

Shaun Dobson/Gillian Martin

+44 207 496 3000

About Skyepharma

Skyepharma combines proven scientific expertise with validated proprietary drug delivery technologies to develop innovative oral and inhalation pharmaceutical products.  The Group is eligible for revenues from 16 approved products in the areas of inhalation, oral, topical and injectable drug delivery as well as generating income from the development of further products and technology licenses.  The products developed by the Group are marketed throughout the world by big pharma as well as speciality pharmaceutical companies.  For more information, visit www.skyepharma.com


This information is provided by RNS
The company news service from the London Stock Exchange
ENDMSCLFFLLRAISIIS
distributed by